D. E. Shaw & Co., Inc. Dyne Therapeutics, Inc. Transaction History

D. E. Shaw & Co., Inc.

$125 Billion
Q2 2025

A detailed history of D. E. Shaw & Co., Inc. transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 508,940 shares of DYN stock, worth $8.63 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

508,940

Previous 287,653 76.93%

Holding current value

$8.63 Million

Previous $3.01 Million 61.07%

% of portfolio

0.0%

Previous 0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$6.81 - $14.78 $1.51 Million - $3.27 Million	221,287 Added 76.93%	508,940 $4.85 Million
Q1 2025 May 15, 2025	BUY	$10.46 - $25.46 $1.61 Million - $3.92 Million	153,881 Added 115.03%	287,653 $3.01 Million
Q4 2024 Feb 14, 2025	BUY	$23.56 - $35.55 $1.43 Million - $2.16 Million	60,732 Added 83.15%	133,772 $3.15 Million
Q3 2024 Nov 14, 2024	SELL	$31.94 - $47.04 $491,237 - $723,475	-15,380 Reduced 17.39%	73,040 $2.62 Million
Q2 2024 Aug 14, 2024	BUY	$23.65 - $35.63 $2.09 Million - $3.15 Million	88,420 New	88,420 $3.12 Million
Q1 2023 May 15, 2023	BUY	$10.88 - $15.0 $113,391 - $156,330	10,422 Added 78.68%	23,668 $272,000
Q4 2022 Feb 14, 2023	BUY	$9.37 - $13.8 $124,115 - $182,794	13,246 New	13,246 $153,000
Q1 2021 May 17, 2021	SELL	$14.0 - $29.3 $143,920 - $301,204	-10,280 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$16.81 - $23.94 $172,806 - $246,103	10,280 New	10,280 $216,000

Others Institutions Holding DYN

# of Institutions

212

Shares Held

122M

Call Options Held

36.5K

Put Options Held

74.3K

View Full List

About Dyne Therapeutics, Inc.

Ticker DYN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,765,400
Market Cap $878M
Description
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...

More about DYN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account